Printer Friendly

MicroMed's Landmark Implantation of DeBakey VAD in 300th Patient; VAD Granting Hope and Better Lives to Hundreds.

HOUSTON -- MicroMed Technology Inc., a world leader in miniaturized implantable ventricular assist technology, announced today it has achieved a significant medical milestone by implanting the 300th patient with its new generation ventricular assist device, the DeBakey VAD(R). Designed in collaboration with NASA, the Baylor College of Medicine, Drs. Michael DeBakey and George Noon, the device is intended for end-stage heart failure patients who can no longer provide necessary blood flow with their native heart.

The device was implanted at the University of Alabama at Birmingham (UAB) University Hospital by Dr. James K. Kirklin, director of Heart and Lung Transplantation, at UAB. Dr. Kirklin was assisted by Dr. William Holman, professor in Surgery, at UAB. The patient is a 48-year-old man suffering from ischemic cardiomyopathy. The DeBakey VAD was implanted as a bridge to heart transplantation under MicroMed's clinical trial for that indication. According to the doctor, prior to the implantation of the MicroMed DeBakey VAD, the condition of the patient rapidly deteriorated and required support with multiple medications to maintain adequate blood pressure. After progressively worsening, the patient underwent successful placement of the DeBakey axial flow VAD.

"The ease of implantation, reliability, small size and silence are the major reasons why we use the MicroMed DeBakey VAD in our patients," said Dr. Kirklin.

"We are very pleased that we have reached this significant milestone which represents continued market acceptance of our next generation miniaturized technology," said Travis Baugh, president and CEO of MicroMed. "We are grateful that renowned cardiac surgeons and cardiologists in key heart centers across the country, like Dr. Kirklin and the team at UAB, have helped us reach this milestone. Our experience with Bridge to Transplant patients worldwide gives us a strong foundation to initiate our Destination Therapy clinical trial, which was started late last year."

The miniaturized DeBakey VAD represents the newest generation of implantable mechanical ventricular support for advanced heart failure. Its design addresses significant limitations of first generation systems such as weight, size, noise, reliability and high rates of infection. It is intended to be highly durable and is the size of a "C" cell battery, measuring only 1"x 3", weighing only 4 ounces compared to over two pounds for currently marketed implantable VADs in the U.S.

About MicroMed Technology

Designed in collaboration with NASA, the Baylor College of Medicine and Drs. Michael DeBakey and George Noon, the DeBakey VAD is intended for end-stage heart failure patients who can no longer provide necessary blood flow with their native heart. The DeBakey VAD is approved for use in two pivotal clinical trials under FDA Investigational Device Exemptions for both Destination Therapy and Bridge to Transplantation. The DeBakey VAD system has been awarded the CE mark for both Bridge to Transplant and Destination Therapy, for commercial distribution in Europe. The DeBakey VAD Child, already commercially released through an HDE in the U.S. and CE mark approved, utilizes the same technology for support of pediatric patients.

MicroMed Technology Inc. is a privately held company that develops products for patients with end-stage, congestive heart failure (CHF). MicroMed's headquarters and ISO 9001 certified Class 10,000 clean room manufacturing facility is located in Houston. For more information, visit
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 23, 2005
Previous Article:Release 1.0 Announces Flight School: A Workshop for the Next Generation of Aerospace Entrepreneurs and Investors.
Next Article:Russell Reynolds Associates Hires Nancy Mistretta.

Related Articles
Experts urge funding for artificial heart.
Wound Care treatment. (Product Focus: Pressure Relief).
Hearing instruments.
Cochlear implantation in severe traumatic brain injury and paranoid schizophrenia: two case studies.
Eisai Announces Results of Overseas Clinical Trials of Donepezil in Treating Vascular Dementia.
Psychosocial issues for patients with ventricular assist devices: a qualitative pilot study.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters